Lenz Therapeutics Announces Licensing Agreement Milestone With Lotus for VIZZ in South Korea and Southeast Asia

LENZ Therapeutics, Inc.

LENZ

0.00

LOTUS PHARMACEUTICALS INC

LTUS

0.00

Lenz Therapeutics Inc. announced that Lotus Pharmaceutical has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) in South Korea for VIZZ, a treatment for presbyopia in adults. This submission is the first under the exclusive license and commercialization agreement signed in May 2025 between Lenz Therapeutics and Lotus Pharmaceutical, which covers South Korea and certain Southeast Asian countries. Under the agreement, Lenz Therapeutics is eligible to receive up to $125 million in regulatory and commercial milestone payments, as well as tiered, double-digit royalties on future net sales. Lotus Pharmaceutical holds exclusive rights for the development, manufacturing, registration, and commercialization of VIZZ in South Korea and several Southeast Asian countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lenz Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9593999-en) on December 01, 2025, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.